Cargando…
State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?
Peripheral arterial disease is an increasingly prevalent condition with significant associated morbidity, mortality, and health care expenditure. Endovascular interventions are appropriate for most patients with either ongoing symptoms of intermittent claudication despite lifestyle and medical optim...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581461/ https://www.ncbi.nlm.nih.gov/pubmed/36268042 http://dx.doi.org/10.1016/j.jscai.2022.100439 |
_version_ | 1784812631399333888 |
---|---|
author | Mosarla, Ramya C. Armstrong, Ehrin Bitton-Faiwiszewski, Yonatan Schneider, Peter A. Secemsky, Eric A. |
author_facet | Mosarla, Ramya C. Armstrong, Ehrin Bitton-Faiwiszewski, Yonatan Schneider, Peter A. Secemsky, Eric A. |
author_sort | Mosarla, Ramya C. |
collection | PubMed |
description | Peripheral arterial disease is an increasingly prevalent condition with significant associated morbidity, mortality, and health care expenditure. Endovascular interventions are appropriate for most patients with either ongoing symptoms of intermittent claudication despite lifestyle and medical optimization or chronic limb-threatening ischemia. The femoropopliteal segment is the most common arterial culprit responsible for claudication and the most commonly revascularized segment. Endovascular approaches to revascularization of the femoropopliteal segment are advancing with an evolving landscape of techniques for arterial access, device-based therapies, vessel preparation, and intraprocedural imaging. These advances have been marked by debate and controversy, notably related to the safety of paclitaxel-based devices and necessity of atherectomy. In this review, we provide a critical overview of the current evidence, practice patterns, emerging evidence, and technological advances for endovascular intervention of the femoropopliteal arterial segment. |
format | Online Article Text |
id | pubmed-9581461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-95814612022-10-19 State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? Mosarla, Ramya C. Armstrong, Ehrin Bitton-Faiwiszewski, Yonatan Schneider, Peter A. Secemsky, Eric A. J Soc Cardiovasc Angiogr Interv Article Peripheral arterial disease is an increasingly prevalent condition with significant associated morbidity, mortality, and health care expenditure. Endovascular interventions are appropriate for most patients with either ongoing symptoms of intermittent claudication despite lifestyle and medical optimization or chronic limb-threatening ischemia. The femoropopliteal segment is the most common arterial culprit responsible for claudication and the most commonly revascularized segment. Endovascular approaches to revascularization of the femoropopliteal segment are advancing with an evolving landscape of techniques for arterial access, device-based therapies, vessel preparation, and intraprocedural imaging. These advances have been marked by debate and controversy, notably related to the safety of paclitaxel-based devices and necessity of atherectomy. In this review, we provide a critical overview of the current evidence, practice patterns, emerging evidence, and technological advances for endovascular intervention of the femoropopliteal arterial segment. 2022 2022-08-20 /pmc/articles/PMC9581461/ /pubmed/36268042 http://dx.doi.org/10.1016/j.jscai.2022.100439 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Mosarla, Ramya C. Armstrong, Ehrin Bitton-Faiwiszewski, Yonatan Schneider, Peter A. Secemsky, Eric A. State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title | State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title_full | State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title_fullStr | State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title_full_unstemmed | State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title_short | State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet? |
title_sort | state-of-the-art endovascular therapies for the femoropopliteal segment: are we there yet? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581461/ https://www.ncbi.nlm.nih.gov/pubmed/36268042 http://dx.doi.org/10.1016/j.jscai.2022.100439 |
work_keys_str_mv | AT mosarlaramyac stateoftheartendovasculartherapiesforthefemoropoplitealsegmentarewethereyet AT armstrongehrin stateoftheartendovasculartherapiesforthefemoropoplitealsegmentarewethereyet AT bittonfaiwiszewskiyonatan stateoftheartendovasculartherapiesforthefemoropoplitealsegmentarewethereyet AT schneiderpetera stateoftheartendovasculartherapiesforthefemoropoplitealsegmentarewethereyet AT secemskyerica stateoftheartendovasculartherapiesforthefemoropoplitealsegmentarewethereyet |